Opioids and chronic neuropathic pain

New England Journal of Medicine

Volumn 348, Issue 13, 2003, Pages 1279-1281

  Foley, Kathleen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; FENTANYL; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OPIATE; OXYCODONE; PLACEBO;

ALLODYNIA; ANALGESIA; CLINICAL TRIAL; DNA POLYMORPHISM; DOSE CALCULATION; DOSE RESPONSE; DRUG CROSS TOLERANCE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TOLERANCE; EDITORIAL; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; NERVE INJURY; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME;

ANALGESICS, OPIOID; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HUMANS; LEVORPHANOL; METHADONE; NEURALGIA;

EID: 0037468688     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe030014     Document Type: Editorial

References (13)

1. Sindrup HJ, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.
2. Carver A, Foley K. Facts and an open mind should guide clinical practice. Curr Neurol Neurosci Rep 2001;1:97-8.
3. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223-32.
4. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990;43:273-86.
5. Dellemijn P. Are opioids effective in relieving neuropathic pain? Pain 1999;80:453-62.
6. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology 2002;58:554-63.
7. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 1999;79:15-20.
8. Chicurel ME, Dalma-Weiszhausz DD. Microarrays in pharmacogenomics - advances and future promise. Pharmacogenomics 2002;3:589-601.
9. Moulin DE, Ling GS, Pasternak GW. Unidirectional analgesic cross-tolerance between morphine and levorphanol in the rat. Pain 1988;33:233-9.
10. Codd EE, Shank RP, Schupsky JJ, Raffa BB. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 1995;274:1263-70.
11. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999;289:1048-53.
12. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16:3216-21.
13. Cherny NU, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995;76:1283-93.